Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Successful Desensitization for Hydroxychloroquine Anaphylaxis

CARMEN DÍAZ DONADO and ELENA MAQUIERA DÍEZ
The Journal of Rheumatology September 2010, 37 (9) 1975-1976; DOI: https://doi.org/10.3899/jrheum.091453
CARMEN DÍAZ DONADO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cdiazd@seaic.es
ELENA MAQUIERA DÍEZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Hydroxychloroquine (HCQ) is an antimalarial agent with immunosuppressive and cytotoxic properties. HCQ is a cornerstone in the treatment of systemic lupus erythematosus (SLE) and rheumatoid arthritis1,2. It has multiple beneficial effects. Exanthema/rash is the most common side effect. About 10% of patients treated with HCQ develop skin eruptions, some due to hypersensitivity. Other patterns of cutaneous hypersensitivity reactions have also been described with antimalarials1,2.

Our patient, a 48-year-old man, had had as many as 11 attacks of pericarditis in less than 2 years, leading finally to a diagnosis of SLE. Once treatment with HCQ was initiated, there were no further attacks. He received treatment with HCQ over a period of 6 months with no notable incident. It was then necessary to interrupt the HCQ for approximately 2 weeks due to an intercurrent illness. Coinciding with resumption of treatment with HCQ 200 mg, he showed symptoms of anaphylaxis (blood pressure alterations, generalized urticaria, and chest pains) and required attention in the emergency room. He was referred to the Allergy Unit. Anaphylaxis due to HCQ was diagnosed, based on positive skin tests, and HCQ was stopped.

On 3 occasions during the 3-month period when he was without treatment with HCQ, he required treatment using cycles of oral corticoids due to reappearance of pericarditis symptoms. He declined to take corticosteroids on a longterm basis although the progression of his pathology made this appear to be necessary. Faced with the negative clinical situation and the lack of longterm treatment alternatives that would be as efficient and safe as HCQ, the patient and his rheumatologist asked us to carry out a desensitization procedure.

The patient was informed that there existed no previous protocols for desensitization with this drug and of the high risk involved in such a procedure. A written consent document was signed and it was decided that the procedure be carried out close to the Intensive Care Unit (ICU), without hospitalization but with the patient monitored and with a peripheral intravenous line.

In order to determine the initial dose, skin-prick tests were carried out with duplicate 10-fold serial dilutions of HCQ. Dilutions in saline solution of 0.002, 0.02, 0.2, 2.0, and 20.0 mg/ml were used. Ten control procedures were also carried out using atopic and non-atopic subjects. Skin test results are shown in Table 1.

View this table:
  • View inline
  • View popup
Table 1.

Result of skin tests.

The procedure commenced with an oral dose of 0.2 mg (1 ml of the solution of 0.2 mg/ml). This concentration had produced a papule that was similar to that produced by the saline solution used as a negative control. See Table 2 for details of the procedure.

View this table:
  • View inline
  • View popup
Table 2.

Desensitization procedure.

It was decided that a procedure of weekly increases be followed. Tryptase control procedures were carried out before and after the increase in the dose. On the following day, in the Allergy Unit, the patient repeated the last dose tolerated on the previous day, this being the dose that he was to take at home each day for the following 6 days. After 4 sessions the maintenance dose was reached.

The skin test study with HCQ was repeated at the different concentrations after completing the procedure, having reached the dose of 100 mg.

The HCQ skin tests showed dose-dependent sensitivity to the product. All skin tests in atopic and non-atopic control subjects were negative.

The patient tolerated the desensitization procedure with no incidents. A dose of 100 mg/day was reached in 4 sessions. No changes were observed in the tryptase values before or after the dose increases. The skin tests carried out at the end of the process of desensitization, with the same 10-fold serial dilutions, were totally negative, all the dilutions producing a papule similar to that of the saline solution.

From a clinical point of view the patient has progressed favorably. Over a period of 9 months, he has been treated with HCQ 100 mg per day, showing no further disease symptoms.

HCQ is pivotal in the treatment of rheumatological disease. Since no other available option was comparable to HCQ in terms of efficacy/safety in the long term, it was decided that desensitization to HCQ should be tried in the allergic patient. Desensitization to a number of medications is performed under circumstances where no good alternative is available for an allergic patient. Such procedures have been carried out for decades with patients allergic to penicillin3. In recent years numerous publications have referred to procedures of desensitization to chemotherapy drugs carried out with success, safety, and efficacy in numerous patients4,5,6. We found only one study of desensitization to HCQ7, involving 4 patients who developed a rash coinciding with administration of the drug, and who then tolerated the procedure. However, with the exception of one patient in whom the rash reappeared when HCQ was reintroduced, in the remaining 3 patients there are no data to confirm hypersensitivity to HCQ and which would consequently allow use of the term desensitization according to Sontheimer8.

The mechanism by which tolerance is induced is not fully understood. Both mastocytes in the blood and cutaneous mastocytes became tolerant. This is shown by the negative results of the HCQ skin tests carried out after desensitization, proving the success of the procedure.

The induction of tolerance does not affect the therapeutic effects. Our patient’s progression was very favorable with the treatment.

This relatively short oral procedure of 28 days, without hospitalization, proved to be efficient and safe. No reactions of any type were observed. It is probable that the success of this study was partly the result of simultaneous treatment with nonsteroidal antiinflammatory drugs on a daily basis. Pretreatment with acetylsalicylic acid and montelukast has proven to be a good measure in rapid desensitization procedures9. Both pretreatments improve tolerance to these procedures by decreasing the number of reactions and consequently decreasing the use of corticosteroids and antihistamines. At the time of writing, the patient continues to tolerate without incident.

This is the first documented case of anaphylaxis due to an allergy to HCQ involving an IgE mechanism. We found no cases in the literature of anaphylaxis due to HCQ. This is also the first case of successful HCQ desensitization as the result of a 4-week procedure not involving hospitalization.

Reactions to drugs where a case of hypersensitivity is suspected should be referred for an allergological study. Many cutaneous drug reactions are self-limiting; however, a priori, it is not possible to know in which cases this will be so. In the case of reactions to HCQ that could lead to temporary or permanent interruption of treatment with this highly efficient and safe drug, it is advisable to consult allergy units specialized in study and treatment of drug-related reactions, in order to establish in which patients it is acceptable to cautiously reintroduce the drug, and those in which it is necessary to carry out a desensitization procedure.

Note added in proof: Our patient came for a followup in March 2010, his rheumatologist having requested an increase in drug dose. In January 2010 he had started to experience pains in muscles and joints, and in February suffered another episode of pericarditis. In March we carried out a 2-week desensitization procedure to increase the dose to 200 mg/day. The patient tolerated the treatment without incident. He is currently being treated with 200 mg/day and awaiting a followup examination in 3 months.

    REFERENCES

    1. 1.↵
      1. Rose BD
      1. Rynes RI
      . Antimalarial drugs in the treatment of rheumatic deseases. In: Rose BD, editor. Wellesley, MA: UpToDate; 2010.
    2. 2.↵
      1. Felson DT,
      2. Anderson JJ,
      3. Meenan RF
      . The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990;33:1449–61.
      OpenUrlPubMed
    3. 3.↵
      1. Garai F,
      2. Montgomery RM
      . Further successful desensitization to penicillin. NY State J Med 1953;53:448.
      OpenUrlPubMed
    4. 4.↵
      1. Lee CW,
      2. Matulonis UA,
      3. Castells MC
      . Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005;99:393–9.
      OpenUrlCrossRefPubMed
    5. 5.↵
      1. Castells MC,
      2. Tennant NM,
      3. Sloane DE,
      4. Hsu FI,
      5. Barrett NA,
      6. Hong DI,
      7. et al.
      Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574–80.
      OpenUrlCrossRefPubMed
    6. 6.↵
      1. Macy E,
      2. Bernstein JA,
      3. Castells MC,
      4. Gawchik SM,
      5. Lee TH,
      6. Settipane RA,
      7. et al.,
      8. Aspirin Desensitization Joint Task Force
      . Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol 2007;98:172–4.
      OpenUrlPubMed
    7. 7.↵
      1. Mates M,
      2. Zevin S,
      3. Breuer GS,
      4. Navon P,
      5. Nesher G
      . Desensitization to hydroxychloroquine — experience of 4 patients. J Rheumatol 2006;33:814–6.
      OpenUrlAbstract/FREE Full Text
    8. 8.↵
      1. Sontheimer RD
      . Desensitization to hydroxychloroquine: alternative interpretations. J Rheumatol 2007;34:253–5.
      OpenUrlFREE Full Text
    9. 9.↵
      1. Breslow RG,
      2. Caiado J,
      3. Castells MC
      . Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol 2009;102:155–60.
      OpenUrlCrossRefPubMed
    PreviousNext
    Back to top

    In this issue

    The Journal of Rheumatology
    Vol. 37, Issue 9
    1 Sep 2010
    • Table of Contents
    • Table of Contents (PDF)
    • Index by Author
    • Editorial Board (PDF)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about The Journal of Rheumatology.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Successful Desensitization for Hydroxychloroquine Anaphylaxis
    (Your Name) has forwarded a page to you from The Journal of Rheumatology
    (Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Successful Desensitization for Hydroxychloroquine Anaphylaxis
    CARMEN DÍAZ DONADO, ELENA MAQUIERA DÍEZ
    The Journal of Rheumatology Sep 2010, 37 (9) 1975-1976; DOI: 10.3899/jrheum.091453

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

     Request Permissions

    Share
    Successful Desensitization for Hydroxychloroquine Anaphylaxis
    CARMEN DÍAZ DONADO, ELENA MAQUIERA DÍEZ
    The Journal of Rheumatology Sep 2010, 37 (9) 1975-1976; DOI: 10.3899/jrheum.091453
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One
    Bookmark this article

    Jump to section

    • Article
      • REFERENCES
    • Figures & Data
    • Info & Metrics
    • References
    • PDF
    • eLetters

    Related Articles

    Cited By...

    More in this TOC Section

    • Does the BNT162b2 Vaccine Trigger Antimelanoma Differentiation-Associated Gene 5 Antibody–Positive Interstitial Lung Disease?
    • Duration of Steroid Therapy and Temporal Artery Biopsy Positivity in Giant Cell Arteritis: A Retrospective Cohort Study
    • Desk Rejections: Not Without Due Deliberation
    Show more Letters

    Similar Articles

    Content

    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology

    Resources

    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies

    Subscribers

    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions

    More

    • About Us
    • Contact Us
    • My Alerts
    • My Folders
    • Privacy/GDPR Policy
    • RSS Feeds
    The Journal of Rheumatology
    The content of this site is intended for health care professionals.
    Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
    Print ISSN: 0315-162X; Online ISSN: 1499-2752
    Powered by HighWire